In this video, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on BGB-3111-215, a Phase II trial (NCT04116437) evaluating zanubrutinib in patients with B-cell malignancies who have previously exhibited intolerance to ibrutinib and/or acalabrutinib, which has resulted in discontinuation of treatment. Dr Shadman focuses on patients with chronic lymphocytic leukemia (CLL) and elucidates that based on current data from the trial, most patients do not have recurrence of prior adverse events (AEs) experienced on ibrutinib and/or acalabrutinib when taking zanubrutinib. In those where AEs do reoccur, they are of a lower or equal grade. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

0 Comments

Up next

Autoplay

Phenytoin (Dilantin): Anticonvulsant Drug for Tonic-clonic or Partial Seizures in Epilepsy Patients

1 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

Zanubrutinib in patients with CLL intolerant to ibrutinib and acalabrutinib

Up next

Language